TEVA Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVA) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 74% planned / 26% discretionary
Largest single sale: $892.1K.
Where they traded
Last open-market purchase: September 5, 2025 — 1.0 years ago, by McAvoy David R. .
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Weiss Amir 2 fills | Chief Accounting Officer | Sell | 9,445 | $37.62 | $355.3K | 13,071 −41.9% of holding | |
| Satchi-Fainaro Ronit | Director | Sell | 415 | $37.25 | $15.5K | 111,986 −0.4% of holding | |
| Lippman Evan | EVP, Business Development | Sell 10b5-1 | 18,600 | $36.57 | $680.3K | 25,591 −42.1% of holding | |
| Zaks Tal Zvi | Director | Sell | 17 | $34.87 | $593 | 73,247 −0% of holding | |
| Hughes Eric A | See "Remarks" | Sell 10b5-1 | 25,578 | $34.88 | $892.1K | 134,877 −15.9% of holding | |
| Jover Placid | See "Remarks" | Sell 10b5-1 | 12,827 | $34.88 | $447.4K | 6,774 −65.4% of holding | |
| Shields Matthew | EVP, Global Operations | Sell | 9,989 | $32.19 | $321.5K | None left |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.